Table 3.

Mean overall survival and progression-free survival for various characteristics based on Kaplan–Meier analysis

	Overall survival (n=329)				Progression-free survival (n=207)
	Number of individuals	Number of events	Mean (95% CI)	p value	Number of individuals	Number of events	Mean (95% CI)	p value
BMI
Normal	106	91	36.5 (24.6–48.4)	0.47	66	54	37.6 (21.2–54.0)	0.25
Overweight	119	94	49.5 (36.5–62.6)		76	54	51.9 (34.0–69.7)
Obese	104	81	41.0 (28.8–53.2)		65	44	55.4 (37.6–73.3)
Smoking status
Never	101	71	61.2 (45.6–76.8)	<0.01	66	42	65.3 (45.1–85.5)	0.02
Former	118	106	29.2 (20.6–37.7)		73	62	33.8 (20.9–46.1)
Current	62	45	53.1 (32.9–73.3)		45	29	58.0 (31.8–84.3)
Age
<60 years	178	119	69.0 (55.7–82.3)	<0.01	126	75	75.0 (57.9–92.1)	<0.01
≥60 years	151	147	20.8 (15.1–26.5)		81	77	22.9 (14.5–31.2)
Sex
Female	141	107	53.0 (39.9–66.2)	0.10	92	62	63.6 (43.5–79.7)	0.10
Male	188	159	37.9 (29.0–46.9)		115	90	41.8 (28.9–54.7)
Cytogenetics
Intermediate	144	112	51.4 (39.4–63.7)	<0.01	103	77	51.8 (36.4–67.2)	<0.01
Unfavorable	114	101	27.8 (17.3–38.3)		62	51	32.7 (16.7–48.8)
Favorable	25	10	124.2 (90.9–157.5)		22	7	117.8 (76.2–159.5)
Unknown	32	29	25.6 (14.2–37.0)		17	14	25.3 (13.5–37.0)
WBC count
<100×109/L	296	240	44.7 (36.6–52.8)	0.24	186	138	50.0 (38.7–61.4)	0.61
≥100×109/L	33	26	37.8 (17.3–58.2)		21	14	52.7 (23.3–82.1)
AML presentation
De novo	229	147	54.3 (44.1–64.5)	<0.01	147	99	57.2 (43.6–70.9)	<0.01
Secondary	100	75	21.8 (13.1–30.5)		37	34	25.5 (9.9–41.1)
Treatment
1990–1999	213	193	35.3 (27.4–43.2)	<0.01	129	111	38.8 (27.6–50.0)	<0.01
2000–2008	116	73	41.9 (34.0–49.9)		78	41	46.7 (36.4–57.1)

Mean survival and 95% CI were calculated from Kaplan–Meier analyses of overall survival time in months; p values based on log rank (Mantel–Cox) test of equality between different factor levels of each covariate. Boldface entries represent p values significant at P<0.05

CI confidence interval, WBC white blood cell count at diagnosis, AML acute myeloid leukemia